Robyn Karnauskas
Stock Analyst at Truist Securities
(2.37)
# 2,515
Out of 4,761 analysts
182
Total ratings
42.95%
Success rate
-0.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robyn Karnauskas
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Maintains: Hold | $333 → $298 | $303.01 | -1.65% | 12 | Jan 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $65 | $55.83 | +16.42% | 2 | Jan 8, 2025 | |
| MRK Merck & Co. | Downgrades: Hold | $130 → $110 | $89.50 | +22.91% | 11 | Jan 8, 2025 | |
| GILD Gilead Sciences | Maintains: Hold | $82 → $83 | $109.95 | -24.51% | 18 | Aug 15, 2024 | |
| ABBV AbbVie | Reiterates: Buy | $195 → $210 | $202.08 | +3.92% | 8 | Jul 26, 2024 | |
| BMEA Biomea Fusion | Downgrades: Hold | n/a | $3.46 | - | 3 | Jun 11, 2024 | |
| BIIB Biogen | Maintains: Buy | $340 | $140.64 | +141.75% | 17 | May 16, 2024 | |
| CRIS Curis | Maintains: Buy | $26 | $3.10 | +738.71% | 2 | May 15, 2024 | |
| CHRS Coherus BioSciences | Maintains: Buy | $8 → $7 | $1.07 | +554.21% | 13 | May 13, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,135 | $700.33 | +62.07% | 16 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $3.65 | +173.97% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $4.96 | +81.45% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $74 | $12.21 | +506.06% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $10.68 | +115.36% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $21.27 | +125.67% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $11.07 | +351.67% | 8 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $850 | $873.68 | -2.71% | 4 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $456 → $508 | $484.24 | +4.91% | 13 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $36 | $26.30 | +36.88% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $25 | $50.69 | -50.68% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.13 | - | 6 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $68.25 | +105.13% | 5 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $150 | $1.09 | +13,661.47% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $7 | $1.42 | +392.96% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $12.84 | +328.35% | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.60 | - | 4 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $3.03 | +857.10% | 1 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $320 | $22.12 | +1,346.65% | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $4.45 | +237.08% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $5.02 | +398.01% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $85 | $0.53 | +15,937.74% | 1 | Oct 8, 2020 |
Amgen
Jan 8, 2025
Maintains: Hold
Price Target: $333 → $298
Current: $303.01
Upside: -1.65%
Bristol-Myers Squibb Company
Jan 8, 2025
Maintains: Buy
Price Target: $62 → $65
Current: $55.83
Upside: +16.42%
Merck & Co.
Jan 8, 2025
Downgrades: Hold
Price Target: $130 → $110
Current: $89.50
Upside: +22.91%
Gilead Sciences
Aug 15, 2024
Maintains: Hold
Price Target: $82 → $83
Current: $109.95
Upside: -24.51%
AbbVie
Jul 26, 2024
Reiterates: Buy
Price Target: $195 → $210
Current: $202.08
Upside: +3.92%
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $3.46
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $140.64
Upside: +141.75%
Curis
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $3.10
Upside: +738.71%
Coherus BioSciences
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $1.07
Upside: +554.21%
Regeneron Pharmaceuticals
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $700.33
Upside: +62.07%
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $3.65
Upside: +173.97%
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $4.96
Upside: +81.45%
Mar 25, 2024
Reiterates: Buy
Price Target: $74
Current: $12.21
Upside: +506.06%
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $10.68
Upside: +115.36%
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $21.27
Upside: +125.67%
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $11.07
Upside: +351.67%
Mar 22, 2024
Reiterates: Buy
Price Target: $850
Current: $873.68
Upside: -2.71%
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $484.24
Upside: +4.91%
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $26.30
Upside: +36.88%
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $50.69
Upside: -50.68%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $2.13
Upside: -
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $68.25
Upside: +105.13%
Sep 6, 2023
Reiterates: Buy
Price Target: $150
Current: $1.09
Upside: +13,661.47%
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $1.42
Upside: +392.96%
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $12.84
Upside: +328.35%
Dec 6, 2022
Downgrades: Hold
Price Target: n/a
Current: $2.60
Upside: -
Nov 16, 2022
Initiates: Buy
Price Target: $29
Current: $3.03
Upside: +857.10%
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $22.12
Upside: +1,346.65%
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $4.45
Upside: +237.08%
Nov 11, 2020
Initiates: Buy
Price Target: $25
Current: $5.02
Upside: +398.01%
Oct 8, 2020
Initiates: Buy
Price Target: $85
Current: $0.53
Upside: +15,937.74%